secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0000320017-26-000012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata and Kuva extend exclusive negotiation deadline to March 7, 2026 for acquisition
--------------------------------------------------------------------------------

- Amendment to binding term sheet extends expiration from Feb 28 to March 7, 2026.
- Kuva Labs to acquire Lisata via tender offer and short-form merger under Section 251(h).
- No other changes to term sheet; parties continue negotiating purchase agreement.
- Acquisition remains subject to tender offer conditions and regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000012/0000320017-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000012/clbs-20260227.htm
  HTML page:      https://secwatch.observer/filing/0000320017-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer